Smith Genetic Research questions FDA role in opioid crisis

Smith Genetic Research says it discussed the opioid crisis with the FDA and raised questions about the agency’s role in cardiovascular deaths tracked in American Heart Association data from 2011 to 2023. The group also says it presented research arguing opioids are poisonous to the human body. Why it matters: - Smith Genetic Research is framing the opioid crisis as both a public health and regulatory failure. - The group is tying its argument to cardiovascular death data from 2011 through 2023. - The claim could add to pressure for renewed scrutiny of the FDA’s role in opioid regulation. What happened: - Smith Genetic Research said it discussed how the opioid crisis happened with the FDA. - The group said it asked what role the FDA played in the epidemic of cardiovascular deaths shown in American Heart Association data. - The data set referenced by Smith Genetic Research runs from 2011 to 2023. - Douglas Smith is listed as the contact for Smith Genetic Research, LLC. The details: - Smith Genetic Research said it presented research studies it believes show opioids are poisonous to the human body. - The group questioned whether the FDA ignored science or missed it. - The release says a graphic was included to show the questions and science. - Contact information provided includes +1 980-201-1073. - Smith Genetic Research provided social links for Facebook , YouTube , and X . Between the lines: - The release is more an advocacy statement than a conventional research announcement. - The central argument is that opioid harm extends beyond addiction and into cardiovascular mortality. - The wording suggests Smith Genetic Research wants regulators to revisit past decisions with new scientific claims. What’s next: - Smith Genetic Research appears to be using the discussion, graphic and social channels to push its message further. - The release does not say the FDA responded or that any new regulatory action is pending. The bottom line: - Smith Genetic Research is pressing the FDA to account for its role in the opioid crisis and the related rise in cardiovascular deaths.